We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Journal of Antimicrobial Chemotherapy 2009 December
OBJECTIVES: The aim of this study was to assess the in vitro activities of nemonoxacin against Gram-positive cocci with various resistance phenotypes.
METHODS: MICs of nemonoxacin were determined for 798 recently collected (2005-07) and non-duplicate isolates of Gram-positive cocci by the agar dilution method. These isolates included: methicillin-susceptible Staphylococcus aureus (MSSA; n = 100); methicillin-resistant S. aureus (MRSA), including ciprofloxacin-susceptible (n = 50), ciprofloxacin-resistant (n = 100), vancomycin-intermediate (n = 50) and daptomycin-non-susceptible (DNS-MRSA; n = 5) isolates, and community-acquired MRSA (CA-MRSA; n = 101); invasive Streptococcus pneumoniae isolates (n = 150); levofloxacin-non-susceptible (MICs of 4-64 mg/L) S. pneumoniae isolates (n = 30); and enterococci (n = 212), including vancomycin-resistant enterococci (VRE; n = 112).
RESULTS: Nemonoxacin had potent activity against MSSA (MIC(90) of < or =0.03 mg/L), ciprofloxacin-susceptible MRSA (MIC(90) of < or =0.03 mg/L) and CA-MRSA (MIC(90) of 0.06 mg/L). For all invasive S. pneumoniae isolates, the activity of nemonoxacin (MIC(90) of 0.06 mg/L) was similar to that of gemifloxacin and much better than that of levofloxacin (MIC(90) of 2 mg/L) and moxifloxacin (MIC(90) of 0.25 mg/L). Nemonoxacin had a 32- to 64-fold higher activity than levofloxacin against levofloxacin-non-susceptible isolates. Nemonoxacin exerted limited activity against ciprofloxacin-resistant MRSA (MIC(90) of 1 mg/L), vancomycin-intermediate MRSA (MIC(90) of 2 mg/L), DNS-MRSA (MIC(90) of 1 mg/L), vancomycin-susceptible enterococci (MIC(90) of 2 mg/L for Enterococcus faecalis and 4 mg/L for Enterococcus faecium) and VRE (MIC(90) of 4 mg/L for E. faecalis and 16 mg/L for E. faecium).
CONCLUSIONS: Our findings point to a potentially useful role for nemonoxacin in the treatment of infections caused by MSSA, ciprofloxacin-susceptible MRSA and S. pneumoniae with various resistance phenotypes.
METHODS: MICs of nemonoxacin were determined for 798 recently collected (2005-07) and non-duplicate isolates of Gram-positive cocci by the agar dilution method. These isolates included: methicillin-susceptible Staphylococcus aureus (MSSA; n = 100); methicillin-resistant S. aureus (MRSA), including ciprofloxacin-susceptible (n = 50), ciprofloxacin-resistant (n = 100), vancomycin-intermediate (n = 50) and daptomycin-non-susceptible (DNS-MRSA; n = 5) isolates, and community-acquired MRSA (CA-MRSA; n = 101); invasive Streptococcus pneumoniae isolates (n = 150); levofloxacin-non-susceptible (MICs of 4-64 mg/L) S. pneumoniae isolates (n = 30); and enterococci (n = 212), including vancomycin-resistant enterococci (VRE; n = 112).
RESULTS: Nemonoxacin had potent activity against MSSA (MIC(90) of < or =0.03 mg/L), ciprofloxacin-susceptible MRSA (MIC(90) of < or =0.03 mg/L) and CA-MRSA (MIC(90) of 0.06 mg/L). For all invasive S. pneumoniae isolates, the activity of nemonoxacin (MIC(90) of 0.06 mg/L) was similar to that of gemifloxacin and much better than that of levofloxacin (MIC(90) of 2 mg/L) and moxifloxacin (MIC(90) of 0.25 mg/L). Nemonoxacin had a 32- to 64-fold higher activity than levofloxacin against levofloxacin-non-susceptible isolates. Nemonoxacin exerted limited activity against ciprofloxacin-resistant MRSA (MIC(90) of 1 mg/L), vancomycin-intermediate MRSA (MIC(90) of 2 mg/L), DNS-MRSA (MIC(90) of 1 mg/L), vancomycin-susceptible enterococci (MIC(90) of 2 mg/L for Enterococcus faecalis and 4 mg/L for Enterococcus faecium) and VRE (MIC(90) of 4 mg/L for E. faecalis and 16 mg/L for E. faecium).
CONCLUSIONS: Our findings point to a potentially useful role for nemonoxacin in the treatment of infections caused by MSSA, ciprofloxacin-susceptible MRSA and S. pneumoniae with various resistance phenotypes.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app